Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Mental Health America Applauds Numerous Provisions In House Health Care Reform Bill
David L. Shern, Ph.D., President and CEO of Mental Health America, will testify on Tuesday, June 23 before the Health Subcommittee of the Energy and Commerce Committee in a hearing to discuss a comprehensive health care reform bill unveiled last week by the Chairmen of the three lead health care reform committees in the House of Representatives: Energy and Commerce, Ways and Means, and Education and Labor.
generic viagra online
Cholesterol Lowering Drugs May Help Prevent Stroke Recurrence
People who take cholesterol-lowering drugs called statins after a stroke may be less likely to have another stroke later, according to research published in the May 26, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.
News of the day
Crucell Announces Positive Results Of Phase II Rabies Monoclonal Antibody Combination Clinical Study In Philippines
Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL) (SWISS: CRX) today announced the results of a second phase II clinical study of its investigational rabies monoclonal antibody combination, which started in May 2008 in the Philippines.
Public Health

Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation In A Variety Of Cancer Models

Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there has been promising initial interest from pharma companies in the intellectual property of Prospect Therapeutics, Inc. ("Prospect"). In preclinical studies, GCS-100 inhibited blood vessel formation in a variety of cancer models. Development and growth of solid tumors requires new blood vessel growth, or angiogenesis, to deliver oxygen and nutrients to a tumor. Galectin-3 also plays an important role in stimulating angiogenesis in a variety of tissues. The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction on Monday, June 29, 2009 at 12:00 noon. Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn"s Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package. About Prospect Therapeutics, Inc. Prospect"s lead product candidate, GCS-100, is a carbohydrate molecule designed to inhibit the activity of Galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients. Joseph F. Finn, Jr., C.P.A.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009